AU
UK
CA
NZ
IND
US
Dyne Therapeutics (NASDAQ:DYN) saw its shares drop nearly 17%, after the biotech announced a substantial secondary stock offering. While it’s common for biotechnology companies to raise cash following encouraging clinical data, the size of Dyne’s new offering caught investors off guard. The company revealed …
Phreesia (NYSE:PHR) experienced a steep 23% decline, after releasing its fiscal third-quarter results. The reaction came as a surprise to many observers, given that the healthcare services technology company reported meaningful improvements across key performance metrics.Revenuefor the quarter rose 13%year over yearto slightly above …
Structure Therapeutics (NASDAQ:GPCR) saw a major surge in interest after releasing positive topline results from its Phase 2b clinical trial evaluating aleniglipron, its oral GLP-1–based obesity therapy. The data immediately captured market attention, driving the stock sharply higher as confidence grew around the drug’s …
Warby Parker (NYSE:WRBY), known for reshaping the eyewear retail experience, is stepping further into the world of wearable technology. The company gained renewed attention after Google highlighted progress on itsAI-powered glasses project. The collaboration includes Google (NASDAQ:GOOGL), Samsung, and eyewear brand Gentle Monster, forming …
Wave Life Sciences (NASDAQ:WVE) made headlines on Monday after announcing interim results from a Phase 1 clinical trial of its investigational weight loss drug, WVE-007. The drug demonstrated a 4.5% reduction in total body fat over three months, compared to no meaningful change in …
Regencell Bioscience Holdings Ltd (NASDAQ:RGC) closed atUSD 16.07on December 05, reflecting a rise of17.0c (1.1%)from the prior session. The move compared with theNASDAQ-100, which added85.5 points (0.3%)during the day. The stock’s relative price increase of0.7%against the index placed it ahead of the broader benchmark …
Gilead Sciences (NASDAQ:GILD), through its Kitesubsidiary, presented new data reinforcing the performance and consistency of its CAR T-cell therapy, Yescarta, in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). The analysis combined four-year outcomes from the Phase 3 ZUMA-7 trial and two-year …
Ascentage Pharma Group International (NASDAQ:AAPG) presented new clinical results from its Phase Ib/II trial evaluating Lisaftoclax (APG-2575) in combination with azacitidine during the 67th American Society of Hematology Annual Meeting. The trial focused on patients with newly diagnosed or prior venetoclax-exposed myeloid malignancies, including …
HUTCHMED Limited(NASDAQ:HCM)announced renewed inclusion of three key oncology therapies—ELUNATE®, ORPATHYS® and SULANDA®—in China’s updated National Reimbursement Drug List (NRDL), effective January 1, 2026. The renewed listing follows a contract renewal with the National Healthcare Security Administration, reflecting continued recognition of these therapies within China’s …
Structure Therapeutics (NASDAQ:GPCR) announced that it will publish topline results from its ACCESS clinical program evaluating aleniglipron, the company’s once-daily oral GLP-1 receptor agonist for obesity, before the market opens on December 8, 2025. Anticipation is high as the company works to advance an …
Please wait processing your request...